Silverback Therapeutics Inc. (SBTX): Price and Financial Metrics

Silverback Therapeutics Inc. (SBTX): $5.87

0.06 (+1.03%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add SBTX to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#175 of 385

in industry

SBTX Price/Volume Stats

Current price $5.87 52-week high $8.97
Prev. close $5.81 52-week low $2.80
Day low $5.72 Volume 116,700
Day high $6.15 Avg. volume 337,931
50-day MA $5.39 Dividend yield N/A
200-day MA $4.38 Market Cap 211.66M

SBTX Stock Price Chart Interactive Chart >


Silverback Therapeutics Inc. (SBTX) Company Bio


Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was founded in 2016 and is headquartered in Seattle, Washington.


SBTX Latest News Stream


Event/Time News Detail
Loading, please wait...

SBTX Latest Social Stream


Loading social stream, please wait...

View Full SBTX Social Stream

SBTX Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!